Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Total Current Liabilities (2020 - 2025)

Bioventus (BVS) has disclosed Total Current Liabilities for 5 consecutive years, with $161.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Current Liabilities changed N/A year-over-year to $161.8 million, compared with a TTM value of $161.8 million through Sep 2025, changed N/A, and an annual FY2024 reading of $210.4 million, up 19.89% over the prior year.
  • Total Current Liabilities was $161.8 million for Q3 2025 at Bioventus, down from $185.7 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $304.0 million in Q4 2022 and bottomed at $160.8 million in Q3 2023.
  • Average Total Current Liabilities over 5 years is $206.5 million, with a median of $185.7 million recorded in 2025.
  • The sharpest move saw Total Current Liabilities soared 68.1% in 2022, then plummeted 44.22% in 2023.
  • Year by year, Total Current Liabilities stood at $180.9 million in 2021, then surged by 68.1% to $304.0 million in 2022, then tumbled by 42.27% to $175.5 million in 2023, then increased by 19.89% to $210.4 million in 2024, then decreased by 23.12% to $161.8 million in 2025.
  • Business Quant data shows Total Current Liabilities for BVS at $161.8 million in Q3 2025, $185.7 million in Q2 2025, and $210.4 million in Q4 2024.